|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號(hào) | CS9981 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
| CAS編號(hào) | |
| 抗體名 | Anti-NFKBIA/IKB alpha |
| 克隆性 | |
| 靶點(diǎn) | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識(shí)物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human IKB alpha |
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：
1. 核因子κB抑制蛋白α抗體費(fèi)用 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價(jià)結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。
產(chǎn)品訂購信息：
英文名稱 Anti-NFKBIA/IKB alpha
中文名稱 核因子κB抑制蛋白α抗體費(fèi)用
別 名 Inhibitor of KB alpha; I kappa B alpha; I(Kappa)B(alpha); IkappaBalpha; IKBA; IKBalpha; MAD 3; MAD3; Major histocompatibility complex enhancer binding protein MAD3; NF kappa B inhibitor alpha; NFKBI; NFKBIA; Nuclear factor of kappa light chain gene enhancer in B cells; Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha; IKBA_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat
產(chǎn)品類型 一抗
研究領(lǐng)域 免疫學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶
蛋白分子量 predicted molecular weight: 36kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human IKB alpha
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
核因子κB抑制蛋白α抗體費(fèi)用 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Three major forms of IKB like molecules have been identified and each is characterised by multiple copies of ankyrin repeats. IKB alpha and IKB beta appear to be the major regulatory forms of IKB in most cells. These proteins interact with p65 or cRel containing forms of NFkB and block nuclear import by masking the nuclear localisation sequences of NFkB. The activation of NFkB involves the inducible phosphorylation and subsequent degradation of IKB. Immunoblotting easily detects the hyperphosphorylated forms of IKB alpha, but not phosphorylated IKB beta. Interestingly, IKB alpha and IKB beta mediate different NFkB responses. IkB alpha appears to control more transient activation of NFkB in response to an inducer, while IKB beta controls a persistent response. Bcl3 interacts with p50 and p52 containing forms of NFkB, but rather than being an inhibitor it appears to function to stimulate transcription. The degradation of IKB is confirmed by immunoblotting.
Function : Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers in the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by immune and proinflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription.Subunit : Interacts with RELA; the interaction requires the nuclear import signal. Interacts with NKIRAS1 and NKIRAS2. Part of a 70-90 kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14. Interacts with HBV protein X. Interacts with RWDD3; the interaction enhances sumoylation. Interacts (when phosphorylated at the 2 serine residues in the destruction motif D-S-G-X(2,3,4)-S) with BTRC. Associates with the SCF(BTRC) complex, composed of SKP1, CUL1 and BTRC; the association is mediated via interaction with BTRC. Part of a SCF(BTRC)-like complex lacking CUL1, which is associated with RELA; RELA interacts directly with NFKBIA. Interacts with PRMT2. Interacts with PRKACA in platelets; this interaction is disrupted by thrombin and collagen. Interacts with HIF1AN.Subcellular Location : Cytoplasm. Nucleus.Tissue Specificity : Highly expressed in lymph node, thymus followed by liver, brain, muscle, kidney, gastrointestinal and reproductive tract.Post-translational modifications : Phosphorylated; disables inhibition of NF-kappa-B DNA-binding activity. Phosphorylation at positions 32 and 36 is prerequisite to recognition by UBE2D3 leading to polyubiquitination and subsequent degradation.Sumoylated; sumoylation requires the presence of the nuclear import signal.Monoubiquitinated at Lys-21 and/or Lys-22 by UBE2D3. Ubiquitin chain elongation is then performed by CDC34 in cooperation with the SCF(FBXW11) E3 ligase complex, building ubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin. The resulting polyubiquitination leads to protein degradation. Also ubiquitinated by SCF(BTRC) following stimulus-dependent phosphorylation at Ser-32 and Ser-36.Deubiquitinated by porcine reproductive and respiratory syndrome virus Nsp2 protein, which thereby interferes with NFKBIA degradation and impairs subsequent NF-kappa-B activation.DISEASE : Defects in NFKBIA are the cause of ectodermal dysplasia anhidrotic with T-cell immunodeficiency autosomal dominant (ADEDAID) [MIM:612132]. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. ADEDAID is an ectodermal dysplasia associated with decreased production of pro-inflammatory cytokines and certain interferons, rendering patients susceptible to infection.Similarity : Belongs to the NF-kappa-B inhibitor family.Contains 5 ANK repeats.Database links :UniProtKB/Swiss-Prot: P25963.1Entrez Gene: 282291 CowEntrez Gene: 4792 HumanEntrez Gene: 18035 MouseEntrez Gene: 406188 PigEntrez Gene: 25493 RatOmim: 164008 HumanSwissProt: P25963 HumanSwissProt: Q9Z1E3 Mouse轉(zhuǎn)錄調(diào)節(jié)因子（Transcriptin Regulators）
抗體的鑒定：
1）核因子κB抑制蛋白α抗體費(fèi)用 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力?？贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗(yàn)測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
Anti-GABA-AR Alpha1/FITC 熒光素標(biāo)記γ1氨基受體α1抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-NuMA/FITC 熒光素標(biāo)記核有絲分裂器NuMA蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh BRLF1 立即早期癌基因BRLF1抗體(基因) 規(guī)格 0.2ml
Integrin Beta chain (ITG- Beta3/ITGB3) 整合素-β3(抗原) 0.5mg
HRH2 英文名稱： 組胺受體H2抗體 0.1ml
Rhesus antibody Rh rhIL-18 重組人白細(xì)胞介素18抗體 規(guī)格 0.1ml
Anti-NuMA/FITC 熒光素標(biāo)記核有絲分裂器NuMA蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml
CD4(Rat Troponin T) ELISA Kit 小鼠CD4分子Multi-class antibodies規(guī)格： 48T
Anti-CD2/FITC 熒光素標(biāo)記CD2抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh E-cadherin/CD324 上皮鈣粘附分子抗體 規(guī)格 0.1ml
sPLA2 (Rat secreted phospholipase A2,sPLA2) ELISA Kit 大鼠分泌型磷脂酶A2 96T
MTMR2 英文名稱： 肌管素相關(guān)蛋白2抗體 0.2ml
Angiopoietin 2 英文名稱： 生成素2抗體 0.1ml
Anti-CD2/FITC 熒光素標(biāo)記CD2抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-phosphoM-CSF Receptor(Tyr809) /FITC 熒光素標(biāo)記兔抗人、大、小鼠磷酸化巨噬細(xì)胞集落刺激因子受體抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-NRP-2/FITC 熒光素標(biāo)記神經(jīng)纖毛蛋白-2抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh BNIP1/TRG8 Bcl2相互作用蛋白1抗體(轉(zhuǎn)化相關(guān)基因8蛋白) 規(guī)格 0.1ml
GLP-2(Glucagon-like peptide-2) 胰素樣肽-2(多肽抗原) 0.5mg
HIPK2 英文名稱： Fas相互作用蛋白激酶2抗體 0.2ml
Rhesus antibody Rh Reg3 beta 胰島β細(xì)胞生長因子Reg IIIα 抗體 規(guī)格 0.2ml
Anti-NRP-2/FITC 熒光素標(biāo)記神經(jīng)纖毛蛋白-2抗體IgGMulti-class antibodies規(guī)格： 0.2ml
MSRVMedium，Modified
L-BacterialHypertonicSaltBroth
緩沖蛋白胨水(BPW) Buffered Peptone Water 250 用于沙門氏菌前增菌培養(yǎng)，亦可用于李氏菌前增菌培養(yǎng)(GB、SN標(biāo)準(zhǔn))
pH7.2磷酸鹽緩沖液250g/瓶0.03mol/L，用于樣品制備和稀釋(國家消毒技術(shù)規(guī)范)incubationmediapH7.2磷酸鹽緩沖液250g/瓶0.03mol/L，用于樣品制備和稀釋(國家消毒技術(shù)規(guī)范)
RODAC接觸皿(TSA)(6.5cm) 10個(gè)/包 用于環(huán)境、器皿、設(shè)備和表面的無菌檢測
科瑪嘉大腸桿菌顯色培養(yǎng)基M0302-0ml/瓶
技術(shù)瓊脂 (3號(hào)瓊脂) (LP0013) Oxoid 500g incubation media 技術(shù)瓊脂 (3號(hào)瓊脂) (LP0013) Oxoid 500g
鹿皮色曲霉 支/瓶
ModifiedLaurylSulfateTryptoseBroth-VancoMycin
AntibioticAgarNO.2
核因子κB抑制蛋白α抗體費(fèi)用 亞碲酸肉湯培養(yǎng)基基礎(chǔ) 250(g) incubation media 亞碲酸肉湯培養(yǎng)基基礎(chǔ) 250(g)
葡萄球菌增菌肉湯 250(g) incubation media 葡萄球菌增菌肉湯 250(g)
葡萄球菌選擇性瓊脂 250(g) incubation media 葡萄球菌選擇性瓊脂 250(g)
胺藍(lán)-DNA瓊脂 100(g) incubation media 胺藍(lán)-DNA瓊脂 100(g)
|
|
|
|
|
